Published Date: 16 Feb 2023
Researchers have found that dilating eye drops that children use daily can delay the onset of myopia.
Read Full NewsIrreversible nerve damage to the lower limbs is a common side effect of chemotherapy, yet up to 50% of patients are missing out on vital foot care that could significantly ease their symptoms, according to new research from ...
A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate ...
Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in screening, surgery and personalized treatment are helping more patients live longer.
1.
Understudied mental health challenges among caregivers of cancer patients: A call for targeted support
2.
Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL
3.
Atezolizumab + Cabozantinib Postpones mCRPC Progression.
4.
The hidden costs of cancer for young survivors are derailing their financial futures
5.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
1.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
2.
Unveiling the Invisible: The Transformative Role of Radiomics in Precision Oncology
3.
Understanding the Rare Disease: Werner Syndrome Explained
4.
Navigating the Complexities of Esophageal Cancer Staging
5.
Advancing Cancer Treatment: Precision Pharmaceutical Care in Oncohematology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation